Pipeline
Programs in Development
A lead compound advancing through preclinical research, supported by exploratory series that extend the same multimodal design method into new target classes.
Portfolio
Program stages
GB-101
Synaptiva
Multimodal cholinergic neuromodulation
M1 muscarinic · AChE
Lead program. Mechanism design complete; profiling and validation ongoing.
GB-2xx
Enzymatic Series
Controlled enzyme modulation
Synaptic enzymes
Exploratory chemistry around partial, tunable enzymatic modulation.
GB-3xx
Transporter Series
Reuptake and transport dynamics
Monoamine transporters
Early computational screening; no candidate selected.
GB-4xx
Signaling Series
Downstream pathway modulation
Intracellular cascades
Concept stage, informed by platform receptor models.
Disclosure
Reading this pipeline
All programs shown are investigational research efforts. Stage indicators describe internal research progression only and do not imply regulatory review, clinical trials, or approval of any kind.
Explore the platform